KLK3 and posterior cortical atrophy: The recently published European SAKK 09/10 is a multicentric randomized phase III trial for PCa patients presenting with BCR (defined as two consecutive rises with a last PSA value > 0.1 ng/ml or three consecutive rises) after RP with a PSA nadir of ≤ 0.4 ng/ml and a PSA ≤ 2 ng/ml at randomization.